Tyrosine kinase 2 modulates splenic B cells through type I IFN and TLR7 signaling

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Tyrosine kinase 2 modulates splenic B cells through type I IFN and TLR7 signaling ; volume:81 ; number:1 ; day:29 ; month:4 ; year:2024 ; pages:1-19 ; date:12.2024
Cellular and molecular life sciences ; 81, Heft 1 (29.4.2024), 1-19, 12.2024

Creator: Bodega-Mayor, Irene
Delgado-Wicke, Pablo
Arrabal, Alejandro
Alegría-Carrasco, Estíbaliz
Nicolao-Gómez, Ana
Jaén-Castaño, Marta
Espadas, Cristina
Dopazo, Ana
Martín-Gayo, Enrique
Gaspar, María Luisa
Andrés, Belén de
Fernández-Ruiz, Elena

Contributor: SpringerLink (Online service)

DOI: 10.1007/s00018-024-05234-y

URN: urn:nbn:de:101:1-2407112059496.568851808326

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:56 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Bodega-Mayor, Irene
Delgado-Wicke, Pablo
Arrabal, Alejandro
Alegría-Carrasco, Estíbaliz
Nicolao-Gómez, Ana
Jaén-Castaño, Marta
Espadas, Cristina
Dopazo, Ana
Martín-Gayo, Enrique
Gaspar, María Luisa
Andrés, Belén de
Fernández-Ruiz, Elena
SpringerLink (Online service)

Other Objects (12)

Correction: Tyrosine kinase 2 modulates splenic B cells through type I IFN and TLR7 signaling

Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7

Deoxyguanosine is a TLR7 agonist

AXL receptor tyrosine kinase modulates gonadotropin-releasing hormone receptor signaling

DUSP4 modulates RIG-I- and STING-mediated IRF3-type I IFN response

Enhanced IFN-α production is associated with increased TLR7 retention in the lysosomes of palasmacytoid dendritic cells in systemic lupus erythematosus

TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activation

Hochschulschrift

TLR7 signaling in human plasmacytoid dentritic cells

Tickling the TLR7 to cure viral hepatitis

Hochschulschrift

Characterization of TLR7-independent effects of Imidazoquinolines

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

The role of TLR7 agonists in modulating COVID-19 severity in subjects with loss-of-function TLR7 variants

Correction: Tyrosine kinase 2 modulates splenic B cells through type I IFN and TLR7 signaling

Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7

Deoxyguanosine is a TLR7 agonist

AXL receptor tyrosine kinase modulates gonadotropin-releasing hormone receptor signaling

DUSP4 modulates RIG-I- and STING-mediated IRF3-type I IFN response

Enhanced IFN-α production is associated with increased TLR7 retention in the lysosomes of palasmacytoid dendritic cells in systemic lupus erythematosus

TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activation

Hochschulschrift

TLR7 signaling in human plasmacytoid dentritic cells

Tickling the TLR7 to cure viral hepatitis

Hochschulschrift

Characterization of TLR7-independent effects of Imidazoquinolines

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

The role of TLR7 agonists in modulating COVID-19 severity in subjects with loss-of-function TLR7 variants

Correction: Tyrosine kinase 2 modulates splenic B cells through type I IFN and TLR7 signaling

Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7

Deoxyguanosine is a TLR7 agonist

AXL receptor tyrosine kinase modulates gonadotropin-releasing hormone receptor signaling

DUSP4 modulates RIG-I- and STING-mediated IRF3-type I IFN response

Enhanced IFN-α production is associated with increased TLR7 retention in the lysosomes of palasmacytoid dendritic cells in systemic lupus erythematosus

TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activation

Hochschulschrift

TLR7 signaling in human plasmacytoid dentritic cells

Tickling the TLR7 to cure viral hepatitis

Hochschulschrift

Characterization of TLR7-independent effects of Imidazoquinolines

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

The role of TLR7 agonists in modulating COVID-19 severity in subjects with loss-of-function TLR7 variants

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Tyrosine kinase 2 modulates splenic B cells through type I IFN and TLR7 signaling

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Correction: Tyrosine kinase 2 modulates splenic B cells through type I IFN and TLR7 signaling

Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7

Deoxyguanosine is a TLR7 agonist

AXL receptor tyrosine kinase modulates gonadotropin-releasing hormone receptor signaling

DUSP4 modulates RIG-I- and STING-mediated IRF3-type I IFN response

Enhanced IFN-α production is associated with increased TLR7 retention in the lysosomes of palasmacytoid dendritic cells in systemic lupus erythematosus

TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activation

TLR7 signaling in human plasmacytoid dentritic cells

Tickling the TLR7 to cure viral hepatitis

Characterization of TLR7-independent effects of Imidazoquinolines

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

The role of TLR7 agonists in modulating COVID-19 severity in subjects with loss-of-function TLR7 variants

Correction: Tyrosine kinase 2 modulates splenic B cells through type I IFN and TLR7 signaling

Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7

Deoxyguanosine is a TLR7 agonist

AXL receptor tyrosine kinase modulates gonadotropin-releasing hormone receptor signaling

DUSP4 modulates RIG-I- and STING-mediated IRF3-type I IFN response

Enhanced IFN-α production is associated with increased TLR7 retention in the lysosomes of palasmacytoid dendritic cells in systemic lupus erythematosus

TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activation

TLR7 signaling in human plasmacytoid dentritic cells

Tickling the TLR7 to cure viral hepatitis

Characterization of TLR7-independent effects of Imidazoquinolines

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

The role of TLR7 agonists in modulating COVID-19 severity in subjects with loss-of-function TLR7 variants

Correction: Tyrosine kinase 2 modulates splenic B cells through type I IFN and TLR7 signaling

Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7

Deoxyguanosine is a TLR7 agonist

AXL receptor tyrosine kinase modulates gonadotropin-releasing hormone receptor signaling

DUSP4 modulates RIG-I- and STING-mediated IRF3-type I IFN response

Enhanced IFN-α production is associated with increased TLR7 retention in the lysosomes of palasmacytoid dendritic cells in systemic lupus erythematosus

TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activation

TLR7 signaling in human plasmacytoid dentritic cells

Tickling the TLR7 to cure viral hepatitis

Characterization of TLR7-independent effects of Imidazoquinolines

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

The role of TLR7 agonists in modulating COVID-19 severity in subjects with loss-of-function TLR7 variants

Related objects

Reset password